英派药业-B（07630）早盘涨超11%，截至发稿，股价上涨11.02%，报12.79港元，成交额99.69万港元。
7月30日，英派药业宣布与全球专业制药公司Pharmanovia达成独家合作，授予Pharmanovia在欧洲、中东、北非、澳大利亚及新西兰地区对塞纳帕利用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌维持单药治疗的独家生产、研发及商业化权利。英派药业有望获得总计最高达4.235亿欧元的付款，包括首付款、近期注册里程碑付款及达到相应销售门槛的商业化里程碑付款，以及基于产品净销售额最高至百分之二十几（中二十位数%）的分级特许权使用费。
根据本次独家合作的相关许可协议，英派药业授予Pharmanovia在66个国家（包括全部27个欧盟成员国，以及英国、挪威、冰岛、瑞士、列支敦士登、澳大利亚、新西兰及中东和北非地区国家）对塞纳帕利用于晚期上皮性高级别卵巢癌、输卵管癌及原发性腹膜癌维持单药治疗的独家生产、研发及商业化权利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.